Introduction, disclosures

Introduction Epidemiologic updates Etiologies, including severe primary IGF-1 deficiency, growth hormone gene deletion, Laron syndrome Diagnostic challenges and distinctions between GHD, ISS, and PIGFD in children

Treatment options available for GHD in pediatric patients Pharmacotherapy detailing: Review and updates · Efficacy and safety · Recent literature · Biosimilar considerations · Monitoring parameters · Investigational agents: long-acting (e.g., somapacitan, lonapegsomatropin) Transition to adulthood Counseling points, barriers to care, and patient education Patient cases

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Describe the importance of timely recognition, referral, screening, and diagnosis of GHD, ISS, and PIGFD in children.
• Summarize current recommendations for the diagnosis of pediatric GHD and related disorders.
• Recall present and investigational pharmacotherapeutic options for treatment of pediatric GHD regarding safety, efficacy, transitions of care into adulthood, and other relevant considerations.
• Formulate treatment strategies for pediatric patients with GHD and related disorders, and describe best practices for tracking patient progress.

ACCME Activity #201759867

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure:

Michael Gottschalk, MD, PhD, Clinical Professor of Pediatrics, Chief, Division of Endocrinology/Diabetes, Department of Pediatrics,  University of California, San Diego School of Medicine, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Ipsen.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version